The regulatory effect of galectin-1 is mediated in part through its ability to induce, in an inhibitor of DNA binding 3 (Id3)-dependent manner, the expression of IL-10 in monocytes and monocyte-derived dendritic cells of lung cancer patients.

lung cancer-derived galectin-1 enhances tumorigenic potentiation of tumor-associated dendritic cells by expressing heparin-binding EGF-like growth factor.

Data show that p38 MAPK, ERK1/2, and COX-2 activation are mediators for the galectin-1-promoted tumor progression and chemoresistance in lung cancer.

ectopic expression of galectin-1 in a low-metastatic CL1-0 lung cancer cell line promotes its migration, invasion and epithelial-mesenchymal transition.

Suggest that galectin-1 plays a major role on the tumorigenesis and invasiveness of CD133+ lung adenocarcinoma cells.

galectin-1 inhibition reduces murine lung metastasis with increased CD4(+) and CD8 (+) T cells and reduced cancer cell adherence